Summary: Centessa Pharmaceuticals announced that preclinical data from a non-human primate study of ORX142, an orexin receptor 2 (OX2R) agonist designed to address excessive daytime sleepiness (EDS) in various neurological, neurodegenerative, and psychiatric disorders, will be … [Read more...]